Cerner
Corporation reported 1Q13 earnings after the bell on April 25th. Revenues were
up 6% to $680MM vs. $641.2MM last year, however, below consensus of
$708.4MM due to reduced levels of low-margin technology resale. This had no
material impact on adjusted EPS reported at $.66 up 22% from 1Q12 which beat
consensus of $.63 due to strength in other areas. Q1 bookings were $801MM up
23% year over year and a record for the company in any first quarter. System
sales were down 12% from the same period a year ago which grew 61% reflecting a
tough comp. Gross margin increased substantially to 81.3% up from 78.3% in 4Q12
driven by lower mix of technology resale and strong service margins while
operating margin increased 340 bps compared to 1Q12 to 24.7% as a result of
ongoing operating efficiencies.
The
stock reacted positively soaring ~4.90% to $95.89 sitting near its 52 week high
of $97.52. Management reiterated FY13 revenue of $2.95B-$3.05B and raised it's
FY13 EPS to $2.78-$2.83 up from $2.75-$2.85. Cerner is well
positioned to benefit from market place trends in IT healthcare and meaningful
use healthcare reform. The company has a comprehensive approach to population
health and significant progress is expected from their increased R&D
investment and expanded relationship with Advocate Health Care- the largest
accountable care organization in the U.S. We reiterate our BUY rating on Cerner
Corporation and remain excited for expected margin improvements in addition to
a robust product pipeline that will open up a new footprint of
opportunities.